Even with only the approved CCA-targeted drugs, pemigatinib-targeting fibroblast growth factor receptor (FGFR) fusion and ivosidenib-targeting isocitrate dehydrogenase (IDH)-1 mutation, the median OS still represents less than 22 months in advanced CCA patients (Abou-Alfa et al., 2020; Zhu et al., 2021). This evidence concerns the gene IDH1 and cholangiocarcinoma.